Trial Profile
Tocilizumab and anti-tumour necrosis factor as first biologic agents in patients with rheumatoid arthritis. Efficacy data from the Rheumatic Diseases Portuguese Register.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Sep 2015
Price :
$35
*
At a glance
- Drugs Anti-TNF monoclonal antibodies (Primary) ; Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 02 Sep 2015 New trial record